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Osteocrin (Ostn) is a recently discovered secreted protein
produced by cells of the osteoblast lineage that shows a well
conserved homology with members of the natriuretic peptide
(NP) family. We hypothesized that Ostn could interact with the
NP receptors, thereby modulating NP actions on the skeleton.
Ostn binds specifically and saturably to the NP peptide recep-
tor-C (NPR-C) receptor with a Kd of 5 nM with no binding to
the GC-A or GC-B receptors. Deletion of several of the residues
deemed important for NP binding to NPR-C led to abolition of
Ostn binding, confirming the presence of a “natriuretic motif.”
Functionally, Ostn was able to augment C-type natriuretic pep-
tide-stimulated cGMP production in both pre-chondrocytic
(ATDC5) andosteoblastic (UMR106) cells, suggesting increased
NP levels due to attenuation of NPR-C associated NP clearance.
Ostn-transgenic mice displayed elongated bones and a marked
kyphosis associated with elevated bone cGMP levels, suggesting
that elevated natriuretic peptide activity contributed to the
increased bone length possibly through an increase in growth
plate chondrocyte proliferation. Thus, we have demonstrated
that Ostn is a naturally occurring ligand of theNPR-C clearance
receptor and may act to locally modulate the actions of the natri-
uretic system in bone by blocking the clearance action of NPR-C,
thus locally elevating levels of C-type natriuretic peptide.
Osteocrin (Ostn)3 is a recently discovered novel small
secreted protein with prohormone-like characteristics (1). To
date, the exact role of Ostn has not been elucidated. Limited
homology, however, was observed between Ostn andmembers
of the natriuretic peptide family, suggesting a possible func-
tional link. The natriuretic system, key in the maintenance of
vascular tone and cardiovascular homeostasis, consists of three
related natriuretic peptides (NPs), ANP, BNP, and CNP (2) and
three receptors (NPRs) mediating the biological activity of
these peptides. The GC-A receptor, which preferentially binds
ANP and BNP, and the GC-B receptor, whose cognate ligand is
CNP, are coupled to guanylyl cyclase, producing cGMP as a
secondary messenger (3, 4). The third receptor, NPR-C, has no
guanylyl cyclase activity and binds all three NPs with similar
affinity (5). To date, no specific endogenous ligand has been
identified for NPR-C, and it is thought to act mainly as a clear-
ance receptor (6). However, other biological functions have
been postulated for this receptor (6).
A number of recent reports have demonstrated that the NPs
also play a key role in regulation of the skeleton (7). Mice over-
expressing either BNP (8) or CNP (9) or lacking NPR-C (10)
display elongated bones, whereas mice lacking CNP (11) or a
functional GC-B receptor exhibit dwarfism (12). Interestingly,
we initially identified Ostn in cells of the osteoblast lineage, the
bone-producing cells, which together with its regulatory effects
on these cells suggested a role in bone activity. Given the
homology of Ostn to the NP family and its putative bone regu-
latory action, a role for Ostn as a molecule mediating co-oper-
ation between the natriuretic and skeletal regulatory systems
presented an intriguing possibility.
Investigation of the nature of Ostn interactions with the
natriuretic system in vitro demonstrated specific binding to the
natriuretic clearance receptor (NPR-C) and the ability to aug-
ment NP activity. Furthermore, overexpression of Ostn using
the collagen type I promoter in transgenic mice resulted in
enhanced bone growth associated with elevated cGMP levels.
We, therefore, propose a role for Ostn as a specific NPR-C
ligand capable of modulating local levels of CNP and its effects
on skeletal development.
EXPERIMENTAL PROCEDURES
Reagents
Rat ANP-(1–28) and CNP-(1–22) were purchased from
Sigma. The cGMP EIA (Biotrak System) was from Amersham
Biosciences. The C-terminal synthetic mouse peptides, Ostn-
(107–129) (amidated) (106YDHSKKRFGIPMDRIGRNRL-
SNSR129) andOstn-(117–130) (116CMDRIGRNRLSNSRG130),
were from Sigma and Affinity BioReagents (Golden, CO),
respectively. These peptides are consensus mammalian
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sequences for these regions of the Ostn protein. The human
peptides Ostn-(83–133) and 125I-labeled Ostn-(83–133) were
purchased from Phoenix Peptides (Belmont, CA).
Cell Culture
Humanembryonickidneycells (HEK293)andratosteosarcoma
cells (UMR106) were maintained in Dulbecco’s modified Eagle’s
mediumwith 10% fetal calf serum (Invitrogen). Mouse pre-chon-
drocytic cells, ATDC5, were maintained in 1:1 Ham’s/F-12
(Invitrogen) with 10% fetal calf serum (Cansera), 1 mM glutamine
(Wisent), 100 g/ml streptomycin, 100 units/ml penicillin
(Wisent), 30nMsodiumselenite (Sigma), and10g/ml transferrin
(Sigma). Exact experimental conditions are described below.
Vectors
To generate a secreted placental alkaline phosphatase-Ostn
fusion protein (PLAP-Ostn), the mouse Ostn sequence cover-
ing amino acids 29–130 was amplified by PCR with forward
5-tctctgtcgacttagcatcagg-3 and reverse 5-ccatcagcctctg-
gaactggagag-3 primers. The PCR product was digested with
SalI (underlined) and cloned into an XhoI/PmeI-digested
pAPtag5 vector containing the PLAP sequence (GenHunter,
Nashville, TN).
The resulting PLAP-Ostn plasmid and the pAPtag5 were
transiently transfected into HEK293 cells (QBiogene, Carlsbad,
CA) using Effectene (Qiagen, Mississauga, ON, Canada). The
day after transfection, cells were washed and incubated for 48 h
in serum-free Dulbecco’s modified Eagle’s medium. The condi-
tioned medium was collected, cells and debris were spun out,
and the supernatant was stored at 4 °C after buffering with 20
mM HEPES (pH 8). Quantification of the PLAP-Ostn fusion
protein was assayed by direct enzyme-linked immunosorbent
assay using the Ostn-(107–129) peptide as standard curve.
Briefly, samples and standards were mixed with carbonate
buffer 100 mM (pH 10) and bound onto high protein-binding
capacity polystyrene (Corning Costar) 96-well plates for 1 h at
37 °C. Wells were washed, blocked with 5% skim milk in Tris-
buffered saline-Tween (TBST) for 1 h at 37 °C, incubatedwith the
anti-Ostnantibody (1:2500 inTBSTwith2.5%skimmilk) for1hat
37 °C, then washed and incubated with an anti-rabbit antibody
linked to horseradish peroxidase (Sigma) (1:30,000 in TBST with
2.5% skimmilk) for 45min at 37 °C. Revelation was achieved with
o-phenylenediamine dihydrochloride Sigma Fast substrate
(Sigma) in the dark for 30 min and read on amicroplate reader at
492 nm. SDS-PAGE and Western blotting against Ostn was also
performed to confirm the presence of the fusion protein.
The expression plasmid for rat GC-A containing the entire
coding sequence cloned between the NheI-KpnI sites of cyto-
megalovirus-driven pBK plasmid (Stratagene, La Jolla, CA) was
kindly provided by Dr. A. De Le´an (De´partement de Pharma-
cologie, Universite´ deMontre´al). The humanNPR-C andGC-B
coding sequences were amplified by RT-PCR from human
embryonic kidney poly(A) RNA (Clontech, Palo Alto, CA) with
the following primer pairs: NPR-C, 5-agggcaagctctttcttgcg-3
(forward) and 5-gggcttcctttaagctactg-3 (reverse); GC-B,
5-ctgctgctttatccccatgg-3 (forward) and 5-ggtttacaggagtccag-
gag-3 (reverse). The resulting PCR products were then cloned
downstream of the cytomegalovirus promoter into the
pcDNA1.1 plasmid (Invitrogen). All constructs were validated
by DNA sequencing.
Recombinant HumanOstn
To produce a bacterial human Ostn (recombinant human
Ostn (rhOstn)), its cDNA encoding amino acids 23–133 was
PCR-amplified with oligos 5-gagggtacccgtagatgtaacaacaaca-
gagg-3 (forward) and 5-ctcctgcagttagcctctggaatttgaaagccg-3
(reverse). The purified PCR fragment was digested with KpnI
and PstI and cloned into pQE30 plasmid and transformed into
the Escherichia coli strain SG13009 (Qiagen). The N-terminal
six-histidine-tagged rhOstn was purified from the soluble bac-
terial extract by sonication followed by chromatography
through nickel-nitrilotriacetic acid-Sepharose (Qiagen) and a
Sepharose-SP cationic exchanger (GE Healthcare). The final
rhOstn preparation was estimated to be 95% pure by SDS-
PAGE and silver staining and was quantified by direct enzyme-
linked immunosorbent assay as described above.
Binding Studies
PLAP-Ostn Fusion Protein—Binding studies were performed
as described previously (13–15). Briefly, HEK293 cells were
transiently transfected with the appropriate expression plas-
mids (GC-A, GC-B, or NPR-C) or a negative control (cytomeg-
alovirus-based green fluorescent protein expression plasmid
(pQBIfc3, Qbiogene)). Forty-eight hours later cells were
washed twice with Hanks’ balanced salt solution containing
0.1%D-glucose, 0.5%bovine serumalbumin, 20mMHEPES, and
0.05% NaN3. Binding of the PLAP-Ostn-containing condi-
tionedmediawith orwithout the various peptides (500l total/
well) was performed at 25 °C for 15 min. Cells were washed 6
times with Hanks’ balanced salt solution for 5 min each and
lysed with 10 mM Tris-HCl (pH 8) containing 0.1% Triton
X-100 at 25 °C, and endogenous alkaline phosphatase was inac-
tivated at 65 °C for 10 min. PLAP activity was measured in the
linear range by a standard enzymatic assay using p-nitrophenyl
phosphate as substrate (Sigma).
125I-Labeled Ostn-(83–133)—Intact cell binding studies with
radiolabeled Ostn-(83–133) were carried out in confluent
ATDC5 cells. Briefly, ATDC5 cells were washed in cold phos-
phate-buffered saline then incubated in Ham’s/F-12 plus 0.1%
bovine serum albumin with 50,000 cpm of 125I-labeled Ostn-
(83–133) for 90min at 4 °C with varying concentrations of cold
Ostn-(83–133) competitor. Cells were washed in cold phos-
phate-buffered saline and lysed into 0.5 M NaOH, and the
bound cpm were counted on a Wallac Wizard 1470 gamma
counter (PerkinElmer Life Sciences). Binding curves were ana-
lyzed by nonlinear regression using GraphPad Prism software
(GraphPad Software, San Diego, CA).
cGMP Assays
For cGMP assays, cells were washed and incubated for 10
min in culture media containing 0.1% bovine serum albumin
and 0.25 mM of the phosphodiesterase inhibitor 3-isobutyl-1-
methylxanthine (Sigma) to minimize cGMP degradation.
Treatments were carried out in the presence of 3-isobutyl-1-
methylxanthine for 15 min, and cells were collected in ice-cold
65% ethanol. Cell extracts were assayed in duplicate using
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cGMP Direct Biotrak EIA (Amersham Biosciences) according
to the manufacturer’s protocol.
Generation of Transgenic Mice
Transgenic mice were generated by nuclear microinjection
of a 4454-bp DNA fragment containing the rat collagen 1 1
3.6-kilobase promoter (3500 to 115) (GenBankTM acces-
sion number J04464) and the mouse Ostn coding region. Five
hundred copies were microinjected into the pronuclei of
C3B6F1 fertilized eggs (C57BL/6J x C3H/HeJ F1 hybrid) which
were then transplanted to the oviducts of pseudopregnant fos-
ter mothers using standard protocols at the Transgenic Facility
at the Institut de Recherches Cliniques deMontre´al (16). Three
independent mouse lines, 650, 677, and 688, were generated
arising from three different founders. Genotyping was carried
out by Southern analysis of EcoRI-digested genomic DNAwith
a mouse Ostn coding region probe or by PCR using inter-exon
primers covering theOstn coding region (1). Long bone lengths
were measured using fine calipers on dissected bones. Tail
lengths were measured from anus to tail tip using a ruler. All
measurements were undertaken by the same operator blinded
to the mouse genotype.
For immunohistochemistry, bones were fixed, decalcified,
embedded, and cut according to standard protocols (17). An
Ostn-specific antibody (1) was used for immunolabeling and
visualized with DAKO Envisision  System-HRP (AEC)
(DAKO, Carpinteria, CA) as per the manufacturer’s protocol.
Proliferation of growth plate chondrocytes was assessed using a
proliferating cell nuclear antigen staining kit (Zymed Labora-
tories Inc., San Francisco, CA) on 7-week-old tibiae from
Ostn-Tg and wild type littermates. After immunohistochemis-
try, positively stained cells in the entire growth plate were
counted and expressed as the percentage of total cell number.
Tomeasure cGMP levels in the bones of wild type and trans-
genic mice, 10–14-day-old mice were euthanized, and the
femurs and tibiawere dissected and cleaned of any adjacent soft
tissue. The whole bones including epiphysis, metaphysis,
diaphysis, andmarrow were then immediately homogenized in
1 ml of cold 65% ethanol using a Polytron homogenizer and
stored at 80 °C until assay. For assay, the bone extracts were
spun at 12000 rpm at 4 °C for 10 min, and the supernatant was
evaporated to dryness and resuspended in 1 ml of cGMP assay
buffer. The cGMP assay was then carried out according to the
manufacturer’s protocol using 25-l aliquots as for the cellular
assays.
Northern Blotting
RNA was isolated from whole bones, isolated tissues, or
whole cell lysates using TrizolTM (Invitrogen). Tendons and
muscles were obtained from 3-month-old rats and the bone
tissue from 4-day-old neonates. Northern blots were generated
on nylonmembranes (Osmonics,Westborough,MA) by stand-
ardmethods (18). Filterswere prehybridized for 4 h and hybrid-
ized overnight in Church buffer (19) at 65 °C. The rat Ostn
cDNA probe corresponded to the full coding sequence. A
mouse glyceraldehyde-3-phosphate dehydrogenase cDNA
probe corresponding to 21 to 956 bp of GenBankTM acces-
sion number M32599 was generated by PCR. Probes were
labeled with [-32P]dCTP using a standard random priming
protocol (18).
RT-PCR for Natriuretic Peptide Receptors
RNAwas extracted fromconfluentATDC5prechondrocytes
and UMR106 osteoblasts 7 days post-confluence using TrizolTM.
For RT-PCR, cDNAs were generated with Superscript IITM
reverse transcriptase (Invitrogen) and random hexamer prim-
ing from 2 g of total RNA, and PCR amplification was carried
out with gene-specific primers using Taq DNA polymerase
(Amersham Biosciences). Gene-specific primers (all 5-3) and
conditions were as follows: NPR-A, forward tggatctcaagtgggag-
cacag and reverse gatctgcatagagcacaagc (annealing tempera-
ture 58 °C, 35 cycles, product 261 bp); NPR-B, forward aact-
gatgctggagaaggagc and reverse gcgagtaagatggttgaactggac
(annealing temperature  58 °C, 35 cycles, product 305 bp);
NPR-C, forward ctacatccaaggcagcgagcg and reverse gcaac-
cacagagaagtcccca (annealing temperature 56 °C, 35 cycles,
product 492 bp); 18 S ribosomal RNA, forward tcaagaac-
gaaagtcggagg and reverse ccaactaagaacggccatgc (annealing
temperature  62 °C, 20 cycles, product 324 bp).
RESULTS
Ostn Sequence Homology—Initial analysis of Ostn species
conservation identified Ostn in humans, cows, mice, rats,
chickens, and snakes (1). Further analysis through genomic
data mining has identified Ostn in amphibians (Ambystoma
tigrinum tigrinum, Eastern tiger salamander) and fish (Danio
rerio, Zebrafish) as well as chimpanzee, pig, and dog. Fig. 1
shows the alignment between Ostn protein sequences from
various vertebrate species with strong conservation of the
C-terminal half of Ostn (e.g. human to amphibian  81%
similarity).
Within the Ostn C-terminal region are two highly conserved
putative dibasic motifs (Fig. 1, shaded) which may represent
active processing sites for proteinases. N-terminal microse-
quencing of purified Ostn from the conditioned media of
HEK293 cells stably expressing mouse Ostn revealed the pres-
ence of a fragment starting at Ser80, thus demonstrating proc-
essing at theKKKR site. Processing at theKRR site has not as yet
been demonstrated.
The two dibasic sites delimit similar sequences (Fig. 1,
boxed), which contain motifs found in the NPs (NP-like motifs,
NM). Fig. 2 shows the alignment between the human Ostn
motifs (NM1 and NM2) and NPs. Residues shaded in gray are
well conserved, particularly those marked with asterisks (Phe7,
Gly8, and Arg13, numbered according to CNP) which are con-
sidered important in binding to the NPR-C receptor. Note,
however, the absence of the two cysteine residues present in all
NPs (Fig. 2, shaded black).
Extra-osseous Ostn Expression—Although initially identified
as an osteoblast-specific gene, further analyses of non-osseous
tissues demonstrated Ostn expression in other stromal-derived
tissues. Northern blotting has demonstrated that Ostn was
expressed at significant levels in both leg tendons/ligaments and
skeletal muscle of young adult rats (Fig. 3). Ostn levels appeared
very high in tendons, withweaker expression inmuscle. However,
direct comparisons are difficult to draw due to differing cell den-
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sities and cell population homogeneity in the various tissues.
Preliminary immunohistochemistry localization of Ostn in
long bones and teeth confirmed it is present in knee joint and
periodontal ligaments (supplemental Fig. 1).
Ostn Binding to Natriuretic Peptide Receptors—Two
approaches were used to characterize Ostn binding to NPRs.
First, a heterologous expression system (transiently transfected
HEK293 cells) in conjunction with an Ostn-fusion reporter
(PLAP-Ostn) was utilized to demonstrate receptor-specific
binding. Further characterization of the binding of Ostn to the
NPR-C receptor was then undertaken using an iodinated syn-
thetic C-terminal Ostn peptide (125I-labeled Ostn-(83–133)) in
a pre-chondrocytic cell line (ATDC5) and which endogenously
express natriuretic receptors. These cells have the potential to
differentiate into matrix producing chondrocytes with insulin
treatment. However, for our studies the presence of excessive
matrix would greatly complicate binding studies, and the
expression pattern of the NPRs was most appropriate in the
pre-differentiated confluent state. Functional consequences of
Ostn binding to NPR-C were then demonstrated by an
enhanced cGMP response to CNP treatment in ATDC5 cells
and an osteoblastic cell line, UMR106.
The Ostn fusion protein, PLAP-Ostn, comprised an N-ter-
minal secreted PLAP moiety linked to full-length mouse Ostn
Human      MLDWRLASAHFILAVTLTLWSSGKVLSVDVTTT-EAFDSGVIDVQSTPTVREEKSATDLTAKLLLLDELV 
Chimpanzee MLDWRLASAHFILAVTLTLWSSGKVLSVDVTTT-EAFDSGVIDVQSTPTVREEKSATDLTAKLLLLDELV 
Dog        MLDWRLANAHFILAMTLMLWSSGKVHSVDVAT--EAFDSGVIDVQSPPTVREEKSATNLAAKLLLLNELV 
Bovine     MLDWRLASAHFILAMTLMLWSSGKVFSVGVTT--EAFDSGVLGVQSSPTVREAKSATDLAAKLLLLDELV 
Pig        MMDWRLASVHFILAVTLMLWSSGKVLSMDVTT--KAFDSELIDVEPPPTMTEEKSATDLAAKLLLLDELV 
Mouse      MLDWRLASTHFILAMIVMLWGSGKAFSVDLASQ----EFGTASLQSPPTAREEKSATELSAKLLRLDDLV 
Rat        MLDWRLASAHFLLAMILMLWGSGKAFSVDLAS--EASEFGAESLQSPPTTREEKSATELAAKLLLLDDLV 
Chicken    MLQFQLVVVHLALVITLLQWHSSSVLLAEAAPEP-LEPSAALGMAAHPTASEEKSASSLAAKLLLLDELV 
Salamander MLESRFLCARFLLAVGLIQWNAGRLLQAGAAPE-SSDSSRLLDTGSHSASSEEKAATDLVAKLLLLDELV 
Zebrafish  MLGCGCVLLSCLLTLTLFHCSAESLHIPQGRPE-YVESSVVEGRSVQRGQMEQKTSGALSAKLLLHDQLV 
Python     ------------------------------------------------TASEEKSATDLVAKILLLNELV 
Human      SLENDVIETKKKRSFSGFGSPLDRLSAGSVD-HKGKQRKVVDHPKRRFGIPMDRIGRNRLSNSRG
Chimp      SLENDVIETKKKRSFSGFGSPLDRLSAGSVD-HKGKQRKVVDHPKRRFGIPVDRIGRNRLSNSRG
Dog        SLENDVIETKKKRSFSGFGSPLDRLSAGSVD-HKGKQRKVIDHPKRRFGVPVDRIGGNRLSNSRG
Bovine     SLENDVIETKKKRSFSGFGSPLDRLSAGSVS-HKGKQRKVVDHPKRRFGIPMDRIGRNRLSNSRG
Pig        SLENDVIETKKKRSFSGFGSPLDRLSAGSPD-HKGKQRKVVDHPKKRFGIPVDRIGRNRLPNSRG
Mouse      SLENDVFETKKKRSFSGFGSPLDRLSAGSVE-HRGKQRKAVDHSKKRFGIPMDRIGRNRLSSSRG
Rat        SLENDVFETKKKRSFSGFGSPLDRLSAGSVE-HRGKQRRVVDHSKKRFGIPMDRIGRNRLSSSRG
Chicken    SLENEVTETKKKRSFPGFGSPIDRISATSVD-AKGKQRKVVELPKRRFGVPLDRIGVSRLGNTKG
Salamander SLENDVMETKKKRSFPGFGSPLDRLSAASTE-LKTKQRKVVEHPKRRFGVPLDRIGVNRLSNSRG
Zebrafish  RLENDVIETKRKRSFPGSNTPLDRLSISTMDPKSNKQRKAVELPRRRVSVPIDRIGVGRLPSSRG
Python     SLENDVFETKKKRSFSGFGSPLDRLSVG----LKAKQRKAVELPKKRFGIPLDRIGVNRLSGSRG
                              NM1                           NM2 
FIGURE 1.Alignment ofOstn amino acid sequences fromvarious species.Alignment of Ostn amino acid sequences from11 species. The putative cleavage
sites are shaded, and the two regions with homology to the NPs, NM1 and NM2, are boxed. Sequences were derived as previously described (1) and from
GenBank ESTs CF787546 (pig), CN052128 (salamander), and AL918290 (zebrafish) and Ensembl genome release 21.3b.1, 21.1.1, and pre-release for zebrafish,
chimpanzee, and dog. The human protein is numbered 1–133 for reference.
NM1 (87-95)              FGSPLDRLS 
NM2 (116-124)            FGIPMDRIG 
ANP (1-28)        SLRRSSCFGGRMDRIGAQSGLGCNSFRY
BNP (1-32)     SPKMVQGSGCFGRKMDRISSSSGLGCKVLRRH
CNP (1-22)         GLSKGCFGLKLDRIGSMSGLGC
                        **    * 
FIGURE 2.Ostn homology to theNPs.Amino acid alignment of humanNM1
and NM2with human ANP, BNP, and CNP. Identical residues are shaded gray,
and the cysteines conserved in the NPs but absent in Ostn are shaded black.
The residues important for bindingofNPs toNPR-C and conserved inOstn are
marked by asterisks.
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FIGURE 3. Expression of Ostn in adult rat non-osseous tissues. Northern
blots were generated with total RNA extracted from adult leg tendons/liga-
ments, abdominal muscles, quadriceps, and brain and neonate calvaria and
limbs (whole tibiae and femora). Significant Ostn expression is seen in adult
tendon and to a lesser extent inmuscle. A high level of Ostn expression is also
seen inneonatebonewithnoexpression in adult rat brain. Twentygof total
RNA were loaded. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH)
expression is shown as a loading control.
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(residues 29–130). Conditioned media containing PLAP-Ostn
was used to assess Ostn binding on transiently transfected
HEK293 cells. We first wished to establish the specificity of
PLAP-Ostn for the different NPRs. Saturable binding of the
PLAP-Ostn fusion proteinwas observed exclusively onNPR-C-
overexpressing cells (Fig. 4A). No
specific binding was seen on cells
overexpressing either green fluores-
cent protein, GC-B (Fig. 4A) or
GC-A (not shown). To verify func-
tionality of the overexpressed
receptors, intracellular cGMP levels
were measured in transfected
HEK293 cells upon stimulationwith
the appropriate ligand. As expected,
ANP elicited the greatest response
via GC-A and CNP through GC-B,
indicating the receptors were func-
tionally expressed in this heterolo-
gous system (Fig. 4B). Because of the
presence of endogenous GC-A in
HEK293 cells, low levels of cGMP
were also induced by ANP after
transfection with either GC-B or
NPR-C (Fig. 4B). Consistent with
absence of PLAP-Ostn binding to
GC-A or GC-B, both a C-terminal
Ostn peptide encompassing NM2
(Ostn-(107–129)) (see Fig. 2) or a
recombinant form of human full-
length Ostn (rhOstn) failed to
activate either GC-A or GC-B
(Fig. 4B).
To investigate the role of the
proposed natriuretic motifs in
Ostn binding to NPR-C, two syn-
theticOstn peptides,Ostn-(107–129)
described above and Ostn-(107–
129), lacking part of NM2, were
used for competition binding stud-
ies. HEK293 cells transfected with
NPR-C were co-incubated with
30 nM PLAP-Ostn and increasing
concentrations of Ostn-(107–129)
or Ostn-(107–129). Ostn-(107–
129) was able to compete off 50% of
the binding of PLAP-mouse Ostn in
the 109–108 M range, in con-
trast to Ostn-(107–129), which was
unable to efficiently compete up to
107 M (Fig. 4C).
Having established that Ostn
binds to the NPR-C receptor and
that at least the NM2 motif was
important for this interaction, we
further characterized binding in
ATDC5 cells which express both
GC-B and NPR-C receptors (Fig.
4E, inset) (20, 21). Competitive binding experiments with
125I-labeled Ostn-(83–133) and increasing concentrations of
cold Ostn-(83–133) gave an average Kd of 4.8  0.9 nM with
a curve characteristic of competitive binding for a single
receptor site (Fig. 4D).
FIGURE 4. Characterization of binding of Ostn to the NPR-C receptor and its effects on ANP activity.
A, PLAP-Ostnbinding toNPR-C-is specific and is saturable. Identical nonspecific bindingof PLAP-Ostn toGC-A-,
GC-B-, or green fluorescent protein-transfected cells was observed. Only results for the green fluorescent
protein and GC-B binding are shown for clarity (mean S.D.; n 4). B, functional validation of the GC-A and
GC-B constructs by transient transfection in HEK293 cells. Levels of cellular cGMPwere measured after 15 min
of incubation with 10 nM ANP, CNP, Ostn-(107–129), or rhOstn. No induction of cGMPwas seen in response to
Ostn-(107–129) or rhOstn. Northern blotting shows similar levels of expression of the transfected receptors.
Data are representative of three independent experiments performed in triplicate. C, displacement curve of
PLAP-Ostn (30 nM) by Ostn-(107–129) or Ostn-(107–129) peptides in NPR-C-overexpressing HEK293 cells. Data
are representative of three independent experiments performed in triplicate. D, displacement curve of 125I-
labeled Ostn-(83–133) (50,000 cpm) by Ostn-(83–133) in ATDC5 cells. Data are representative of four separate
experiments each with three replicates. E, augmentation of cGMP induced by 107 and 106 M CNP by co-
treatmentwith 107 MOstn-(83–133) inATDC5prechondrocytes. ExpressionofNPRswas confirmedbyRT-PCR
in triplicate (inset). *, p  0.01, CNP versus CNP  Ostn-treated. The figure is representative of two separate
experiments each with three replicates. F, augmentation of cGMP induced by 107–106 M CNP by co-treat-
ment with 107 M Ostn-(83–133) in UMR106 osteoblasts. Expression of NPRs was confirmed by RT-PCR (inset).
The figure is representative of two separate experiments eachwith three replicates. Kd values for binding data
were calculated using GraphPad Prism (GraphPad Software). Comparisons of CNP versus CNP/Ostn treatment
were made by analysis of variance using Statview (SAS Institute, Cary, NC).
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Binding of Ostn to NPR-C could result in attenuation of the
clearance action of this receptor, thus increasingNP availability
and cGMP production upon stimulation of GC-A or GC-B.We
tested this hypothesis in ATDC5 and UMR106 cells whereby
NP signaling (cGMP production) was assessed in the presence
or absence of Ostn-(83–133). ATDC5 cells express both GC-B
and NPR-C at confluence (Fig. 4E, inset). When treated with
107 or 106 M CNP, ATDC5 cells produced 10.1  1.9 and
37.0 4.5 ng of cGMP/g of protein, respectively. However, if
the cells were incubated with the same concentrations of CNP
together with 107 M Ostn-(83–133), cGMP production was
augmented 5.2- and 2.2-fold, respectively (p 0.01). UMR106
osteoblasts were used at 7 days post-confluence when both
GC-B and NPR-C were expressed (Fig. 4F, inset). Treatment of
UMR106 with a range of CNP concentrations from 107 to
106 M resulted in a dose-responsive cGMP production. At all
CNP concentrations tested, co-treatment with Ostn aug-
mented cGMP production, with an average increase of 1.4-fold
(p 0.05) (Fig. 4F). Using the heterologous HEK293model, we
showed thatOstn could not compete off either ANPorCNP for
the endogenous GC-A or the overexpressed GC-B receptors,
respectively (see supplemental Figs. 2 and 3). However, in both
cases Ostn could effectively compete with either ANP or CNP
for the NPR-C receptor, with concomitant activation of their
respective cognate receptors and increase in intracellular
cGMP accumulation (supplemental Figs. 2 and 3).
Characterization of Ostn Transgenic Mice—Reflecting the
initial identification of Ostn in osteoblastic cells, we investi-
gated its role in the skeleton in vivo by generating transgenic
mice utilizing the rat 3.6-kilobase collagen type I promoter to
overexpress mouse Ostn in osteoblast-lineage cells (Ostn-TG)
(22). It should be noted, however, that the collagen type I pro-
moter also drives expression in the perichondrium, skin, and
tendons (23). Three independent mouse lines were established
and analyzed with all three lines showing similar phenotypes.
Northern blotting confirmed high levels of transgene expres-
sion in bone with no apparent effects on endogenous expres-
sion (data not shown). Immunohistochemical staining demon-
strated elevated Ostn protein levels in osteoblastic cells of
4-day-old Ostn-TG tibiae versuswild type littermates (Fig. 5, A
and B). Clear expression can be seen in the cuboidal osteoblasts
in the primary spongiosa and surrounding periosteum, sites
rich in osteoblasts. Expression was also seen in the perichon-
drium surrounding the growth plate (a known site of collagen
type I expression). Ostn-TGmice displayed no gross physiolog-
ical defects, with similar body weight to their wild type litter-
mates. Life spans of the Ostn-TG mice appeared normal with
no evidence of early death up until 12 months of age. Bone
mineral density aswell as lean and fatmass, asmeasured by dual
energy x-ray absorptiometry (DEXA) in 8-month-old mice
from the three transgenic lines, showed no significant differ-
ences between transgenic and wild type littermates. All three
Ostn-TG mice lines did exhibit one significant phenotype, how-
ever, that of elongated limbs and tails and amarked kyphosis (Fig.
5, C and D). The kyphosis and elongated tail length were evident
from weaning and were present throughout the adult life of the
mouse. The kyphosis was presumably due to elongated vertebrae
causing a spinal deformation. Measurements of tail (Fig. 5G) and
femur (Fig. 5H) lengths in8-week-oldmales in the650 line showed
15 and12% increases, respectively, comparedwithwild type litter-
mates (p  0.01). Overall, across the three transgenic lines, tail-
length was increased 14.5 1.2% (p 0.01) and the length of all
long-bones by 7.1 0.4% (p 0.05) (n 8–13). An underlying
cause of increased bone length could be changes in the growth
FIGURE 5. Ostn-transgenic (Ostn-TG) mice have longer bones. Ostn-TG
mice with overexpression of Ostn in osteoblast lineage-specific cells were
generated using the 3.6-kilobase collagen type I promoter. Immunohisto-
chemistry using anOstn-specific antibodyon4-day-old tibia ofwild type (WT)
(A) and Ostn-TG (B) mice. Ostn expression in WT is non-detectable (A),
whereas overexpression in Ostn-TG is evident (red staining) on cuboidal
osteoblasts adjacent to trabecular bone of the primary spongiosa (arrows)
andwithin theperichondrium (arrowheads) (B). Counter stain ismethyl green.
The scale bar is 200m. C andD, gross appearance of WT (C) and Ostn-TG (D)
which have a marked kyphosis presumably due to vertebral overgrowth.
E and F, proliferation in growth plate chondrocytes wasmeasured in tibiae of
7-week-old male mice using proliferating cell nuclear antigen immunohisto-
chemistry. Proliferating chondrocytes are clearly more abundant in Ostn-TG
(F) mice than WT littermates (E). Tail (G) and femur (H) lengths of 8-week-old
Ostn-TG line 650males are significantly longer thanwild type littermates (n
7–12). I, quantification of proliferating cell nuclear antigen immunohisto-
chemistry showed an 80% increase in staining of growth plate chondrocytes
(n  4) (J). cGMP levels were significantly higher in 10–14-day-old Ostn-TG
mice femurs and tibiae than theirWT littermates (n 11–28). p 0.05 (*) and
p  0.01 (**), Ostn-TG versus WT. Data are expressed as the mean  S.E.
Comparison were made by analysis of variance using Statview.
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plate. Analysis of the growth plate in 7-week-old male tibiae
showed no significant changes in the width of proliferative of
hypertrophic zones, but a doubling in proliferation in the growth
plate chondrocytes was seen by proliferating cell nuclear antigen
labeling (p 0.05; n 4) (Fig. 5, E–F and I).
To determine whether the increases in bone length in
Ostn-TG mice could be due to increased NP signaling, cGMP
levels were measured in the femurs and tibias of these animals.
Levels of cGMP in 10–14-day-old Ostn-TG bones were 77%
higher than in wild type littermates (p  0.05)(Fig. 5J), thus
confirming Ostn was modulating NP activity in bone.
DISCUSSION
Previously we have reported the identification and initial
characterization of Ostn (1). Further analysis of the extensive
sequence databases now available provided confirmation of the
presence of Ostn across a range of mammalian, bird, and
amphibian species. Interestingly, it should be noted, however,
that the homology is reduced in zebrafish (54% similarity), and
Ostn has not yet been identified in the puffer fishes Fugu
rubripes and Tetraodon nigroviridis. Such departure from the
stronger conservation evident in higher vertebrates may repre-
sent the differing requirements for salt and water homeostasis
in fish. Furthermore, differences in the cellularity of bone, such
as osteocyte numbers and, thus, skeletal physiology, may fur-
ther explain the absence of Ostn in Fugu (24, 25).
The most consistent homology between species for Ostn lies
in the C-terminal region of the protein, and it is this region that
displays homology to the NPs.Most interestingly, the best con-
served homology with theNPs includes the residues Phe7, Gly8,
and Arg13 (numbering according to CNP) that have been dem-
onstrated to be necessary for peptide binding to the NPR-C
receptor (26–28). Furthermore, the lack of the two cysteine
residues present in all NPs indicates Ostn does not form the
cyclic ring structure that is essential for binding to the receptors
signaling through cGMP, GC-A, and GC-B (29, 30). Interest-
ingly, synthetic ring-deleted, linear analogues of the NPs such
as des-Cys105, Cys121-(104–126), C-ANF (des-18QSGLG22-
ANP (4–23)), and AP-811 have been shown to be specific
ligands of NPR-C (26, 28, 31–33), suggesting that Ostn and its
derived proteolytic peptides could represent specific, naturally
occurring ligands of NPR-C.
Specific and saturable binding of Ostn to overexpressed
NPR-Cwas demonstrated in vitro, and this binding appeared to
be mediated through the natriuretic motif that we identified
(Fig. 2). Previous studies have estimated the Kd of other NPR-
C-specific ligands, such as AP-811 and C-ANF, for the NPR-C
receptor to be in the high picomolar/low nanomolar range (26,
28, 33, 34). Thus, our estimate of a Kd of5 nM in ATDC5 cells
appears to be an appropriate affinity to enable functionality.
More importantlyOstnwas capable of attenuating the inhib-
itory action of NPR-C on the ability of both ANP and CNP to
stimulate their cognate receptors GC-A and GC-B. Thus, we
demonstrated that full-length Ostn protein or a fragment
thereof can bind to NPR-C and partially block its clearance
activity toward NPs thereby restoring signaling.
Overexpression of Ostn in the bones of transgenic mice lead
to a significant increase in bone length and a marked kyphosis
(presumably due to vertebral overgrowth). This Ostn-TG phe-
notype was strikingly reminiscent of the NPR-C knock-out
mice (10, 35) as well as the BNP- andCNP-overexpressingmice
(36, 37). In all cases, bone overgrowth presumably correlated
with increased NP bioavailability. The presence of the GC-A
and GC-B receptors and production of cGMP in response to
NPs has been well established in both osteoblasts (38–43) and
chondrocytes (21, 44–47).
Although blocking of the NPR-C receptor may result in
increased bioavailability of all three NPs, CNP is considered to
be the major effector in bone. Mice lacking CNP displayed
severe dwarfism associated with reduced growth plate heights
(11), whereas inactivation of either the ANP or BNP locus does
not cause skeletal abnormalities (48, 49). Overexpression of
CNP in chondrocytes rescued achondroplasia (9), and CNP but
not ANP or BNP has been demonstrated to be expressed in
cultured tibiae (50). Thus, we propose a mechanism whereby
Ostn potentiates the effects of CNP on longitudinal bone
growth through binding NPR-C and blocking its clearance
action (Fig. 6).
Previous models demonstrating bone length changes medi-
ated by alterations in CNP/GC-B/NPR-C activity appear to be
GTP
cGMP
CNP
GC-B
NPR-C
internalization
degradation
signaling ?
downstream targets
proliferation
chondrocytes / osteoblasts
GTP
CNP
GC-B
NPR-C
internalization
degradation
signaling ?
downstream targets
proliferation
Ostn
A
B
cGMP
FIGURE 6. Ostn blocks the clearance action of NPR-C thereby increasing
activity of the NPs in the bone compartment. A, both the GC-B and NPR-C
receptors areexpressed inosteoblasts andchondrocytes; thus, theactivityof the
NPs (normally CNP in the skeleton) is governed by the distribution of CNP
between the signal mediating GC-B receptor and the NPR-C clearance receptor.
B, in the presence of Ostn, CNP access to NPR-C is blocked leading to increased
bindingofCNP to theGC-B receptor. This results inan increase inGC-B-mediated
cGMP production, magnifying the downstream biological effects of the natri-
uretic system,which in the skeleton leads to elongated bones.
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due to changes in the growth plate, with altered chondrocyte
proliferation and differentiation (9, 11, 37). Similarly, we saw an
increase in proliferation in growth plate chondrocytes, suggest-
ing Ostn may act to stimulate bone growth through actions on
the growth plate chondrocytes in the same fashion as direct
manipulation of the natriuretic system. CNP antagonism of the
anti-proliferative effects of FGF2/FGFR3 in chondrocytes has
been proposed as a mechanism through which such changes
could occur (51). Interestingly, endogenous Ostn has been
shown to be expressed in mature chondrocytes (52). The
secreted soluble nature of Ostn would also allow its activity
distal to the point of expression allowing osteoblasts adjacent to
the growth plate to exert paracrine effects. Thus, the elevated
Ostn expression in the osteoblasts and perichondrium sur-
rounding the growth plate in the Ostn-TG would also allow
paracrine actions on the chondrocytes.
There ismounting evidence thatNPR-C ismore than a clear-
ance receptor (for review, see Ref. 6). NPR-C-specific ligand
binding has been demonstrated to inhibit adenylate cyclase (53,
54) and modulate ion channel activity (55, 56). Thus, the dis-
covery of an endogenous and specific ligand for NPR-C may
have further significance beyond just quenching of NPR-Cs
clearance function. The role of the natriuretic peptides in adult
bone has not been studied. Interestingly Ostn is down-regu-
lated in aged bone and by 1,25-dihydroxyvitamin D3 (1), which
is reciprocal to NPR-C (39, 57). The potential thus exists for
Ostn to counter the possibly inhibitory effects of increased
NPR-C activity in aged bone and potentially even exert anabolic
effects.
Of further interest is the fact that we have detected expres-
sion ofOstn in othermesenchymal tissues such asmuscle fascia
and tendons corroborating other studies showing muscle
expression (58–61). Expression of Ostn in tendons is of partic-
ular interest due to high levels of CNP seen in tendons and
muscles,4 alluding to a role of Ostn as a modulator of CNP
action in these tissues as well. These tissues all originate from a
common stromal progenitor population presenting an intrigu-
ing role for Ostn in mediating interactions between the natri-
uretic system and tissues of stromal origin.
Thus, we have identified Ostn as the first naturally occurring
NPR-C specific ligand, thereby illustrating another level of reg-
ulation in the action of theNPs and suggesting amechanism for
direct regulatory interaction between the natriuretic pathway
and the skeletal and other mesenchymal systems. The recent
identification of a human syndrome,AcromesomelicDysplasia,
type Maroteaux, which is characterized by dwarfism caused by
a mutation in the GC-B receptor, further highlights the poten-
tial importance of regulation of the natriuretic system in the
skeleton (62). Elucidation of the nature of these interactions
will provide valuable insight into possible therapeutic interven-
tions such aswas recently demonstrated by rescue of achondro-
plasia using CNP (9).
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